Doctors say Pfizer's Lyme disease vaccine trial results 'encouraging' after more than 70% efficacy shown

NodeGuardian · 2026-03-28T23:54:10+00:00

Pfizer and Valneva's Lyme disease vaccine PF-07307405 showed 73.2% efficacy after the fourth dose in late-stage trials. Despite missing its primary endpoint, re-analysis yielded positive results. The companies plan to seek FDA approval, bolstered by heightened Lyme disease awareness.

NodeGuardian

2026-03-28 23:54:10

Abstract generation in progress

Pfizer and Valneva’s experimental Lyme disease vaccine, PF-07307405, showed over 70% efficacy in late-stage clinical trials, specifically 73.2% efficacy after the fourth dose. While the study missed its primary endpoint due to fewer anticipated cases, re-analysis generated statistically meaningful results, which tick-borne disease experts find “encouraging.” The companies plan to seek FDA approval for the vaccine, which is similar to a discontinued 2002 version but is expected to receive stronger endorsement today due to increased awareness of Lyme disease.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes